If you are already in GBM treatment and considering a move to a new hospital or a different country, the fear of disruption is real. But transferring GBM care mid-treatment is something many families do successfully every year. It can give you access to a clinical trial that only runs at one institution, a surgical technique not offered at your first hospital, or a cost of care that is significantly lower than what you are currently paying. The switch does not always mean a gap in treatment. What it does require is a plan.
This guide covers when a transfer makes clinical sense, which records to gather, how to speak with your current team, and what changes when you are crossing an international border rather than moving across town.
How do you transfer GBM care to a new hospital?
- Request all imaging - MRI scans as DICOM files on a digital disc or secure transfer link - along with the radiology report for every scan taken since diagnosis.
- Ask the pathology department to prepare physical slides or a paraffin-embedded tissue block so the new center can run an independent pathology review.
- Obtain a written treatment summary covering every drug used, radiation doses delivered to each field, cycle dates, and any documented adverse events.
- Include current bloodwork (full blood count, metabolic panel, coagulation studies), performance status notes, and any recent steroid dose changes.
- Confirm the new team has received and reviewed all records before booking your first appointment - whether in person or remote.
- If crossing an international border, check whether a medical visa or an oncologist-signed travel clearance letter is required at your destination.
- Agree on who manages urgent questions - medication refills, steroid tapering, seizure control - during the transition window between teams.
When does changing hospitals mid-treatment make sense?
There is no single right moment for a transfer. Transitions between treatment phases (after surgery but before radiation begins, or after chemoradiation ends and adjuvant chemotherapy is about to start) are logistically easier. One chapter is closing; the new team takes over planning for the next rather than stepping into an unfinished course of treatment.
Transfers also happen mid-radiation, mid-chemotherapy, and at recurrence. None of these are impossible. What changes is the complexity of the handover. The new team needs to know exactly how many radiation fractions have been delivered and to which fields, or how many chemotherapy cycles have been completed, before they can continue safely.
Families move care for several reasons. A second opinion might change the molecular diagnosis and open new trial options. A technique like laser ablation or fluorescence-guided resection might only be available elsewhere. Some move for access to an immunotherapy trial. International patients sometimes move because costs are much lower in another country.
The National Brain Tumor Society makes this clear: seeking a second opinion is not disloyal to your doctor, and most neuro-oncologists expect it and will help you get your records.
Which records does a new neuro-oncology team actually need?
A complete handover packet covers several categories. Missing any one of them adds delay at exactly the wrong time.
Imaging. Get every MRI since diagnosis (the pre-operative scan, the post-operative scan ideally taken within 24 to 72 hours of surgery, and all surveillance scans). DICOM format is preferable to printed images because it lets the radiologist adjust contrast windows and perform their own reconstruction. If scans were taken at multiple centers, gather them from each one.
Pathology materials. The original pathology report with the WHO 2021 glioblastoma classification, MGMT methylation status (a marker associated with how well the tumor may respond to chemotherapy), IDH mutation status, and any other molecular markers that were tested. Where possible, request physical slides or an unstained paraffin-embedded block; the new center may want to repeat or extend molecular testing on its own platform. Reading your own pathology report can be confusing; the article What Your Glioblastoma Pathology Report Really Means explains the key terms in plain language.
Treatment summary. A written record of the radiation plan (total dose in Gray - the unit used to measure radiation energy delivered to tissue - fractionation schedule, and treatment fields) plus every systemic agent used, including doses, cycle count, and dates. If Tumor Treating Fields (TTFields) were used, include the protocol start date and average daily usage hours.
Clinical notes. Operative reports from any brain surgery, clinic notes documenting neurological status changes, and records of any complications such as a blood clot, surgical infection, or steroid-related side effects.
Current medications. A full list including the corticosteroid being used and the current dose and taper schedule, anti-seizure drugs with doses, and any prophylactic medications. This is critical for the transition period before the new prescribing physician formally takes over.
If you are assembling a second opinion package for the first time, the guide at How to Prepare for a Glioblastoma Second Opinion goes into detail on organizing these materials and the specific questions to raise at that first consultation.
How to tell your current oncologist you want to leave
Many patients and caregivers worry that raising the idea of a transfer will damage the relationship with the current team. In practice, most neuro-oncologists understand that patients seek additional opinions (particularly at a diagnosis as serious as glioblastoma) and most will help coordinate the release of records without being asked twice.
A straightforward approach works best. You can say something like: "Before we start the next phase of treatment, we want to get a second opinion at another center. Can you help us request the records?" Most institutions have a release-of-records process that your doctor's office can start. Larger academic centers often run formal second-opinion programs. You submit records digitally and get a written review without traveling.
Both Memorial Sloan Kettering and Dana-Farber Cancer Institute run remote second-opinion programs that accept records from international patients. No travel is required for the opinion itself.
If you are not seeking a one-time opinion but intending a full transfer of ongoing care, be clear about that distinction. Your current team needs to know whether to keep scheduling future treatment appointments or to assist with a formal handover to the new center.
Moving GBM care across international borders
International care transfers are more complex but increasingly common. Patients from Africa, Asia, and the Middle East regularly transfer mid-treatment GBM care to specialist centers in India, the United States, the United Kingdom, and Germany. Reasons include access to clinical trials, lower costs, or new treatment options after an international second opinion.
The cost difference between countries can be substantial. A systematic review of global economic differences in GBM care found that total direct medical costs varied enormously by country. In the United States, cumulative direct medical costs reached approximately USD 356,000. In India, the comparable figure was approximately USD 18,900. The difference reflects variation in drug pricing, hospital infrastructure, and health system structure. The full review is available at PMC.
When moving internationally, take several practical steps first. Confirm that the destination hospital accepts international patients for mid-treatment transfers and has a dedicated international patient coordinator. Check whether your existing medical visa covers treatment at the new facility, or if you need a new one. Establish how remote follow-up will work after you return home - who reviews your blood results and who manages your prescriptions.
You can get a remote second opinion through Art of Healing Cancer to see whether a transfer makes sense before you commit to travel. The team reviews your imaging and pathology and explains what a transfer would involve for your specific situation.
The guide to Evaluating an International Glioblastoma Surgeon covers questions to ask when choosing a center abroad, including how to verify surgical volumes, what a tumor board should look like, and whether the technique you need is regularly available.
What the receiving team needs to start quickly
When the receiving center has complete and well-organized records, your first consultation can move directly to clinical planning rather than record-chasing. A few habits help this happen.
Send records ahead of your appointment, not on the day. Most academic neuro-oncology centers want at least five to ten business days to review imaging and pathology before the patient consultation. If the review is remote and you're shipping physical slides internationally, allow extra time for transit and customs clearance.
Bring a concise one-page treatment timeline. This is not a substitute for the full record set, but it lets the physician orient quickly: diagnosis date, surgery date and extent of resection, radiation start and end dates, number of chemotherapy cycles completed, and the date of the most recent MRI. Note molecular marker results prominently (MGMT methylation status, IDH mutation status, TERT promoter status) because these shape every subsequent treatment decision.
Include a current symptoms summary. The new team needs the present neurological picture: any seizures and their type and frequency, language or motor changes since the last MRI, and your current performance status score. This supplements but does not replace the clinical notes transferred from your original center.
The real risks of a mid-treatment transfer and how to reduce them
The main risk is a treatment gap (a period where no active treatment is happening because the transfer is taking longer than expected). When records are incomplete or a physical slide shipment is held at customs, that gap widens. The most effective way to reduce it is to run the transfer in parallel with ongoing treatment rather than stopping treatment first. If you are midway through adjuvant chemotherapy cycles, continue taking your medication as prescribed while the new team reviews your records. Only switch the prescribing physician once the formal intake is complete and the new team has confirmed the plan.
A second risk is incomplete communication. The current team sends a partial record set; the new team does not notice until the appointment. The fix is to request a record-release checklist from the new center in advance, gather every item on that list, and send everything in a single organized packet with a cover note specifying exactly what is included. Follow up by email to confirm receipt.
A third risk for international transfers is regulatory. Some countries require radiation treatment files to be re-created locally because their linear accelerators use different software. If re-irradiation is being planned at the new center, this may significantly affect timing. Ask the receiving radiation oncology team about this before booking any travel.
The National Brain Tumor Society's guidance on second opinions says that leading centers routinely handle remote review requests, and a well-managed transfer rarely delays treatment when both teams stay informed and cooperate from the outset.
When to talk to your doctor
Talk to your current oncologist before you stop any medication, miss a scheduled treatment session, or book international travel related to a planned transfer. Talk to the new team before committing to flights or accommodation. If your situation is complex (for example, if you are on a clinical trial drug that requires a formal protocol transfer, or if your doctors are actively adjusting your corticosteroid dose), ask both teams to communicate directly through a shared written summary or a phone bridge between the two tumor boards.
You can upload your MRI and reports through the Glioblastoma Center patient-journey form for a remote review that helps you decide whether a transfer makes sense before you commit.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.